II

ImageneBio Inc

IMA·NASDAQ

$5.63

+1.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$63.50M
EPS-10.7600
P/E Ratio-0.52
Earnings Date07/23/2026

ima

Operating Income

Last Annual Value

-48.45M

3-Year CAGR

12%

5-Year CAGR

-2%

10-Year CAGR

-2%

II

ImageneBio Inc Competitors Analysis of Operating Income

IMA · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
-48.45M
N/AN/AN/A 
-57.28M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
-122.11M
N/AN/AN/A
-12.20M
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
-103.23M
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-6.69M
N/AN/AN/A
-29.52M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
18.07M
N/AN/AN/A
-104.95M
N/AN/AN/A
-42.44M
N/AN/AN/A
-46.15M
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.63, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.63